Castle Biosciences (CSTL) Equity Average (2018 - 2026)

Castle Biosciences has disclosed Equity Average across 9 years of filings, most recently posting $466.1 million for Q1 2026.

• Equity Average for Q1 2026 came in at $466.1 million, up 4.03% year-over-year; the trailing twelve-month figure through Mar 2026 was $466.1 million (up 4.03% YoY), and the FY2025 annual result was $463.4 million, up 9.4% from the prior year.
• Equity Average came in at $466.1 million for Q1 2026 at Castle Biosciences, down from $469.0 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $469.0 million in Q4 2025 to a low of $382.0 million in Q2 2023.
• The 5-year median for Equity Average is $413.2 million (2024), against an average of $421.4 million.
• Across the five-year window, Equity Average slipped 8.23% in 2023 and grew 15.42% in 2024, its largest moves.
• Castle Biosciences' Equity Average stood at $405.3 million in 2022, then retreated by 4.14% to $388.5 million in 2023, then advanced by 15.42% to $448.4 million in 2024, then gained by 4.57% to $469.0 million in 2025, then slipped by 0.6% to $466.1 million in 2026.
• The last three Equity Average figures came in at $466.1 million (Q1 2026), $469.0 million (Q4 2025), and $461.2 million (Q3 2025), per Business Quant data.